Long-term In Vitro Treatment of Human Glioblastoma Cells with Temozolomide Increases Resistance In Vivo through Up-regulation of GLUT Transporter and Aldo-Keto Reductase Enzyme AKR1C Expression

Benjamin Le Calvé, Michał Rynkowski, Marie Le Mercier, Céline Bruyère, Caroline Lonez, Thierry Gras, Benjamin Haibe‐Kains, Gianluca Bontempi, Christine Decaestecker, Jean‐Marie Ruysschaert, Róbert Kiss, Florence LefrancNeoplasia 2010 · DOI

TL;DR

This study investigates how glioblastoma (GBM) cells develop resistance to the chemotherapy drug temozolomide (TMZ). Researchers found that long-term TMZ treatment leads to increased expression of glucose transporters (GLUTs) and a family of enzymes called AKR1Cs, which may contribute to this resistance and offer new therapeutic targets.

What Problem Does This Paper Address?

Glioblastoma (GBM) is the most aggressive form of brain cancer, and current treatments, including surgery, radiation, and chemotherapy with temozolomide (TMZ), often fail due to the development of drug resistance. While TMZ is a cornerstone of GBM treatment, patients frequently develop resistance, leading to tumor recurrence and poor outcomes. Understanding the molecular mechanisms behind this acquired resistance is crucial for developing more effective therapeutic strategies. This paper aims to identify specific genes and pathways that become altered in GBM cells after prolonged exposure to TMZ, contributing to their reduced sensitivity to the drug.

Methods

The researchers employed a multi-pronged approach to investigate TMZ resistance:

  • In Vitro Drug Resistance Induction: Human GBM cell lines (U373 and T98G) were cultured for extended periods with gradually increasing concentrations of TMZ, up to 1 mM, to induce acquired resistance.
  • In Vivo Xenograft Models: The drug-resistant and sensitive GBM cells were implanted into immunocompromised mice to evaluate their behavior and response to treatment in a living system.
  • Genomic and Proteomic Analysis:
    • Whole-Genome Microarray Analysis: This technique was used to identify global changes in gene expression in both TMZ-sensitive and TMZ-resistant GBM cells.
  • Western Blotting and Immunofluorescence: These protein-level analyses were performed to confirm and visualize the expression of specific genes identified through microarray analysis.
  • Reverse Transcription-Polymerase Chain Reaction (RT-PCR): Used to analyze the mRNA expression of various stem cell markers.
  • Cellular Assays:
    • Computer-Assisted Phase-Contrast Video Microscopy: Employed to monitor cell viability, growth dynamics, and cell division in real-time.
  • Flow Cytometry: Used to analyze cell cycle kinetics.
  • Gene Silencing: Small interfering RNA (siRNA) was used to specifically reduce the expression of AKR1C3 to assess its role in proliferation and chemoresistance.

Datasets

  • Human GBM Cell Lines: U373 and T98G cell lines were used for in vitro experiments.
  • Clinical Samples: A dataset of 159 gliomas and 23 normal brain samples from the Henry Ford Hospital was analyzed for gene expression of GLUT transporters and AKR1C enzymes. This dataset was obtained from the Affymetrix Array Series GSE4290.

Key Insights and Ideas

  • Dual Role of Glucose Metabolism and Drug Metabolism in Resistance: The study highlights that acquired TMZ resistance in GBM cells is linked to significant alterations in both glucose uptake (via GLUT transporters) and drug metabolism pathways (via AKR1C enzymes). This suggests a complex interplay between cellular energy demands and the cell's ability to process or tolerate the drug.
  • GLUT-3 as a Key Player in U373 Aggressiveness: The increased expression of GLUT-3 in U373 TMZ-resistant cells correlated with increased in vitro growth rates and potentially contributed to their enhanced in vivo aggressiveness, suggesting a link between glucose metabolism and tumor progression.
  • AKR1C Proteins as Potential Mediators of Resistance and Proliferation: The significant upregulation of AKR1C1, AKR1C2, and AKR1C3 in resistant cells points to their involvement in maintaining cell viability and promoting proliferation in the face of TMZ treatment.
  • Targeting AKR1C3 Affects Proliferation but Not Direct Chemoresistance: While silencing AKR1C3 reduced the proliferation rate of resistant GBM cells, it did not directly increase their sensitivity to cytotoxic drugs. This suggests AKR1C3's role might be more in supporting the overall growth and survival of resistant cells rather than directly reversing the drug's cytotoxic effect.

Key Results

  • Long-term in vitro treatment of U373 and T98G GBM cells with TMZ led to partial acquired resistance, which was also demonstrated in vivo.
  • TMZ-resistant GBM cells showed increased expression of facilitative glucose transporters (GLUTs), particularly GLUT-3, and the AKR1C family of proteins (AKR1C1, AKR1C2, AKR1C3) at both mRNA and protein levels.
  • U373 TMZ-LTT xenografts exhibited more aggressive behavior in vivo compared to U373 TMZ-S xenografts.
  • In vitro, U373 TMZ-LTT cells displayed higher growth kinetic rates, while T98G TMZ-LTT cells appeared to grow slower.
  • Transient silencing of AKR1C3 in U373 TMZ-LTT GBM cells significantly decreased their global growth rate.
  • Analysis of clinical glioma samples revealed that GLUT-10 mRNA expression levels were maximal in GBMs, and GLUT-3 and GLUT-5 mRNA levels showed heterogeneous patterns across different histopathologic groups.

Limitations and Future Work

  • Partial Resistance Achieved: The study achieved only partial resistance to TMZ, meaning that the cells were not completely insensitive to the drug. This limits the direct translation of findings to fully resistant tumors.
  • Selective Silencing Challenges: The researchers encountered difficulties in achieving selective silencing of AKR1C1 and AKR1C2 due to their high homology, preventing a detailed analysis of their individual roles.
  • Future Directions: The authors suggest that selective targeting of GLUT-3 and/or AKR1C proteins could be a promising strategy to delay the acquisition of TMZ resistance in astroglioma cells. Further research could explore the precise mechanisms by which these proteins contribute to resistance and investigate the efficacy of specific inhibitors, such as jasmonates for AKR1C proteins. The potential role of hypoxia in upregulating GLUT transporters also warrants further investigation.

Summary updated

Abstract

Glioblastoma (GBM) is the most frequent malignant glioma. Treatment of GBM patients is multimodal with maximum surgical resection, followed by concurrent radiation and chemotherapy with the alkylating drug temozolomide (TMZ). The present study aims to identify genes implicated in the acquired resistance of two human GBM cells of astrocytic origin, T98G and U373, to TMZ. Resistance to TMZ was induced by culturing these cells in vitro for months with incremental TMZ concentrations up to 1 mM. Only partial resistance to TMZ has been achieved and was demonstrated in vivo in immunocompromised mice bearing orthotopic U373 and T98G xenografts. Our data show that long-term treatment of human astroglioma cells with TMZ induces increased expression of facilitative glucose transporter/solute carrier GLUT/SLC2A family members, mainly GLUT-3, and of the AKR1C family of proteins. The latter proteins are phase 1 drug-metabolizing enzymes involved in the maintenance of steroid homeostasis, prostaglandin metabolism, and metabolic activation of polycyclic aromatic hydrocarbons. GLUT-3 has been previously suggested to exert roles in GBM neovascularization processes, and TMZ was found to exert antiangiogenic effects in experimental gliomas. AKR1C1 was previously shown to be associated with oncogenic potential, with proproliferative effects similar to AKR1C3 in the latter case. Both AKR1C1 and AKR1C2 proteins are involved in cancer pro-proliferative cell chemoresistance. Selective targeting of GLUT-3 in GBM and/or AKR1C proteins (by means of jasmonates, for example) could thus delay the acquisition of resistance to TMZ of astroglioma cells in the context of prolonged treatment with this drug.
BibTeX
@inproceedings{calve2010long,
  author = {Benjamin Le Calvé and Michał Rynkowski and Marie Le Mercier and Céline Bruyère and Caroline Lonez and Thierry Gras and Benjamin Haibe‐Kains and Gianluca Bontempi and Christine Decaestecker and Jean‐Marie Ruysschaert and Róbert Kiss and Florence Lefranc},
  title = {{Long-term In Vitro Treatment of Human Glioblastoma Cells with Temozolomide Increases Resistance In Vivo through Up-regulation of GLUT Transporter and Aldo-Keto Reductase Enzyme AKR1C Expression}},
  booktitle = {Neoplasia},
  year = {2010},
  doi = {10.1593/neo.10526},
}
Figure